Abstract: A combination for use in treating cancer is provided. The combination comprises a therapeutically effective amount of a quinoxaline derivative of Formula I which inhibits nuclear import protein, Kpn?1, and a therapeutically effective amount of at least one platinum-based chemotherapeutic agent. The combination therapy provides an enhanced anti-cancer therapeutic effect compared to the effect of the compound of Formula I and the at least one platinum-based chemotherapeutic agent administered alone.

Abstract: The invention provides a method, device, kit and computer-implemented method for diagnosing (and optionally also treating) cancer. The method for diagnosing cancer comprises the step of testing a blood sample from a subject suspected of having cancer for the presence of Ipo5 (Importin 5) and at least one other biomarker, the at least one other biomarker being selected from Ran (Ras-related nuclear protein) and KpnB1 (Karyopherin beta 1). The blood sample may also be tested for additional biomarkers such as CRM1 (Cross-Reactive-Material-197), Kpna2 (Karyopherin alpha 2), CAS (Cellular apoptosis-susceptibility protein) and Transportin 1.

Abstract: The present disclosure provides compositions and methods of treating and improving the symptoms of systemic juvenile idiopathic arthritis and polyarticular-course juvenile idiopathic arthritis using an antibody that specifically binds human interleukin-6 receptor (hIL-6R).

Abstract: The present disclosure provides compositions and methods of treating and improving the symptoms of systemic juvenile idiopathic arthritis and polyarticular-course juvenile idiopathic arthritis using an antibody that specifically binds human interleukin-6 receptor (hIL-6R).

Abstract: The present disclosure provides compositions and methods of treating and improving the symptoms of systemic juvenile idiopathic arthritis and polyarticular-course juvenile idiopathic arthritis using an antibody that specifically binds human interleukin-6 receptor (hIL-6R).

Abstract: The invention relates to methods and assays for identifying compounds as candidates in the development of a drug for the treatment of various diseases including those associated with pathological Tau. The invention also relates to methods and assays for identifying compounds for the treatment of various diseases including those associated with pathological Tau. The invention also relates to cell lines and constructs for use in an assay of the invention. The methods and assays identify a compound as useful in the treatment of a tauopathy if said compound modulates Sil1 expression or activity.

Abstract: Embodiments for implementing intelligent alarm sound control by a processor. A targeted entity may be isolated for a generated sound to be delivered, while noise cancellation is simultaneously provided to prevent an alternative entity from being disturbed by the isolated sound.

Abstract: The present invention relates to the use of an anti-IL6 receptor antibody in monotherapy for treating rheumatoid arthritis and for improving the physical function and the quality of life of a subject suffering from rheumatoid arthritis.

Abstract: Implementations of the present invention include a compound and methods for inhibiting karyopherin beta 1 activity by administering to a patient in need thereof a therapeutically effective amount of a substituted benzoxazepine. The compound of Formula II, 9-[(1-methylpiperidin-3-yl)methoxy]-4-[(6-methylpyridin-2-yl)methyl]-7-(5-methylthiophen-2-yl)-3,5-dihydro-2H-1,4-benzoxazepine or one of its salts, inhibits the import of protein and transcription factors, such as NFAT and P65/NFKB into the nucleus of a cell, and thus has anti-cancer effects enabling the compound to be used for cancer treatment.

Abstract: Implementations of the present invention include a compound and methods for inhibiting karyopherin beta 1 activity by administering to a patient in need thereof a therapeutically effective amount of a substituted benzoxazepine. The compound of Formula II, 9-[(1-methylpiperidin-3-yl)methoxy]-4-[(6-methylpyridin-2-yl)methyl]-7-(5-methylthiophen-2-yl)-3,5-dihydro-2H-1,4-benzoxazepine or one of its salts, inhibits the import of protein and transcription factors, such as NFAT and P65/NFKB into the nucleus of a cell, and thus has anti-cancer effects enabling the compound to be used for cancer treatment.

Abstract: Compounds, including quinoxaline derivatives of formula I, for use in the treatment of cancer are described. In general, the compounds inhibit the import of proteins and transcription factors such as Kpn?, AP-1, P65, NFAT into the nucleus of a cell by inhibiting the nuclear import protein, Kpn?1. Cancer cells have elevated levels of Kpn?1 and the inhibition of their nuclear import activity induces cell apoptosis. The administration of an effective amount of any one of the compounds results in cell apoptosis in cancer cells, while non-cancer cells are substantially unaffected by the inhibition of Kpn?1's nuclear import activity.

Abstract: Compounds, including quinoxaline derivatives of Formula (I), for use in the treatment of cancer are described. In general, the compounds inhibit the import of proteins and transcription factors such as Kpn?, AP-1, P65, NFAT into the nucleus of a cell by inhibiting the nuclear import protein, Kpn?1. Cancer cells have elevated levels of Kpn?1 and the inhibition of their nuclear import activity induces cell apoptosis. The administration of an effective amount of any one of the compounds results in cell apoptosis in cancer cells, whilst non-cancer cells are substantially unaffected by the inhibition of Kpn?1's nuclear import activity.

Abstract: The present invention provides compositions and methods of treating and improving the symptoms of rheumatoid arthritis using an antibody that specifically binds human interleukin-6 receptor (hIL-6R).

Abstract: The invention relates to methods and assays for identifying compounds as candidates in the development of a drug for the treatment of various diseases including those associated with pathological Tau. The invention also relates to methods and assays for identifying compounds for the treatment of various diseases including those associated with pathological Tau. The invention also relates to cell lines and constructs for use in an assay of the invention. The methods and assays identify a compound as useful in the treatment of a tauopathy if said compound modulates Sil1 expression or activity.

Abstract: Compositions comprising microcrystalline cellulose, cellulose ether, and salt are provided together with methods for making them. Additionally, there are also described edible food products and industrial suspensions formed from these compositions.

Abstract: Compositions containing microcrystalline cellulose, cellulose ether, and salt are provided together with methods for making them. Additionally, there are also described edible food products and industrial suspensions formed from these compositions.

Abstract: Compositions comprising microcrystalline cellulose, cellulose ether, and salt are provided together with methods for making them. Additionally, there are also described edible food products and industrial suspensions formed from these compositions.